Scott Michael Palmer, MD

Professor of Medicine
Vice-Chair for Research in the Department of Medicine
Member in the Duke Clinical Research Institute
Professor in Immunology
Professor in Population Health Sciences
Core Faculty in Innovation & Entrepreneurship
Campus mail 2085 Msrb2 2 Genome Ct, Durham, NC 27710
Phone (919) 684-0245
Email address scott.palmer@duke.edu

Dr. Palmer leads a successful program of clinical, basic and translational research in lung transplantation, idiopathic pulmonary fibrosis (IPF), bronchiolitis obliterans (BO) and other lung diseases. He directs the Medicine Plus Therapeutic Area at the Duke Clinical Research Institute (DCRI) and serves as Vice Chair for Research in the Department of Medicine. He is also the Director of Clinical Research, Duke Transplant Center.

Dr. Palmer has over 250 peer reviewed publications, received numerous awards, including election into the American Society for Clinical Investigation (ASCI) in 2012, chaired many sessions at national and international meetings, serves regularly on NIH study sections, and is on the editorial board of many prominent journals. He is a dedicated mentor to trainees and junior faculty, having personally mentored over 40 pre-and post-doctoral trainees, many of whom are now engaged in their own successful research careers. He is multiple PI on two Duke R38 awards supporting dedicated resident research, and multiple PI for a Duke Pulmonary T32 training program, all reflecting his deep commitment to support and train the next generation of physician investigators. He has received continuous NIH funding since 2002.

His scientific accomplishments include high impact studies that have demonstrated the importance of innate immunity in transplant rejection, a clinical trial that improved cytomegalovirus (CMV) prevention after lung transplantation, and work that identified rare protein coding exome variants that contribute to the development of IPF.  In addition to these studies he has led numerous multicenter studies, registries and clinical trials.  His program of translational research focuses on the use of human tissue and samples in studying pulmonary transplant rejection, and the use of human airway cells epithelial cells in the study of bronchiolitis obliterans including in the transplant and occupational setting. Recent work has employed single cell RNAseq to discover novel cell types and mechanisms involved in lung disease and transplant rejection.  

Education and Training

  • Fellow, Pulmonary Medicine, Medicine, Duke University, 1996 - 1999
  • Medical Resident, Medicine, Duke University, 1993 - 1996
  • M.H.S., Duke University, 2000
  • M.D., Duke University, 1993

Publications

Zhang, David, Gundula Povysil, Philippe H. Kobeissy, Qi Li, Binhan Wang, Mason Amelotte, Hager Jaouadi, et al. “Rare and Common Variants in KIF15 Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis.” Am J Respir Crit Care Med, April 13, 2022. https://doi.org/10.1164/rccm.202110-2439OC.

PMID
35417304
Full Text

Hostetler, H., M. L. Neely, F. L. Kelly, A. B. Nixon, J. Londry, B. Silva, N. Gulbahce, R. N. Woodward, S. M. Palmer, and J. L. Todd. “Bronchoalveolar Lavage Fluid (BALF) as a Compartment for DonorDerived Cell-Free DNA (dd-cfDNA) Assessment in Lung Recipients.” In Journal of Heart and Lung Transplantation, 41:S155–S155, 2022.

Scholars@Duke

Hostetler, H., M. L. Neely, F. L. Kelly, A. B. Nixon, J. Londry, R. N. Woodward, S. M. Palmer, and J. L. Todd. “Performance of Donor-Derived Cell-Free DNA (dd-cfDNA) for Discriminating Acute Lung Allograft Injury in a Multicenter Cohort.” In Journal of Heart and Lung Transplantation, 41:S74–S74, 2022.

Scholars@Duke

Diamond, J. M., R. Vos, M. Budev, H. J. Goldberg, G. J. Criner, J. M. Pilewski, L. G. Singer, et al. “Y Efficacy and Safety of the Janus Kinase 1 Inhibitor Itacitinib (ITA) in Patients with Bronchiolitis Obliterans (BOS) Syndrome Following Double Lung Transplant.” In Journal of Heart and Lung Transplantation, 41:S113–S113, 2022.

Scholars@Duke

Decato, Benjamin E., Diana Julie Leeming, Jannie Marie Bülow Sand, Aryeh Fischer, Shuyan Du, Scott M. Palmer, Morten Karsdal, Yi Luo, and Anne Minnich. “LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis.” Respir Res 23, no. 1 (March 18, 2022): 61. https://doi.org/10.1186/s12931-022-01980-4.

PMID
35303880
Full Text

Langel, Stephanie N., Francine L. Kelly, David M. Brass, Andrew E. Nagler, Dylan Carmack, Joshua J. Tu, Tatianna Travieso, et al. “E-cigarette and food flavoring diacetyl alters airway cell morphology, inflammatory and antiviral response, and susceptibility to SARS-CoV-2.” Cell Death Discov 8, no. 1 (February 15, 2022): 64. https://doi.org/10.1038/s41420-022-00855-3.

PMID
35169120
Full Text

Todd, Jamie L., Megan L. Neely, Robert Overton, Hillary Mulder, Jesse Roman, Joseph A. Lasky, Joao A. de Andrade, et al. “Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort.” Lung 200, no. 1 (February 2022): 11–18. https://doi.org/10.1007/s00408-021-00505-y.

PMID
35066606
Full Text

Todd, Jamie L., Megan L. Neely, Robert Overton, Hillary Mulder, Jesse Roman, Joseph A. Lasky, Joao A. de Andrade, et al. “Correction to: Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort.” Lung 200, no. 1 (February 2022): 19. https://doi.org/10.1007/s00408-022-00516-3.

PMID
35166906
Full Text

Swaminathan, Aparna, Anne S. Hellkamp, Megan L. Neely, Shaun Bender, Luca Paoletti, Eric S. White, Scott M. Palmer, Timothy Pm Whelan, Daniel F. Dilling, and Daniel F. IPF-PRO Registry investigators. “Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry.” In Ann Am Thorac Soc, 2022. https://doi.org/10.1513/AnnalsATS.202105-589OC.

PMID
35073248
Full Text

Goswami, Ria, Veronica S. Russell, Joshua J. Tu, Charlene Thomas, Philip Hughes, Francine Kelly, Stephanie N. Langel, et al. “Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells.” Iscience 24, no. 12 (December 17, 2021): 103412. https://doi.org/10.1016/j.isci.2021.103412.

PMID
34786537
Full Text

Pages